185 related articles for article (PubMed ID: 16273232)
1. Use of granulocyte colony-stimulating factor: a survey among Italian medical oncologists.
Danova M; Rosti G; De Placido S; Bencardino K; Venturini M
Oncol Rep; 2005 Dec; 14(6):1405-12. PubMed ID: 16273232
[TBL] [Abstract][Full Text] [Related]
2. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
Wong SF; Chan HO
Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
[TBL] [Abstract][Full Text] [Related]
3. Use of granulocyte colony-stimulating factor (G-CSF) in clinical practice in Fukuoka City area in Japan.
Tamura K
Fukuoka Igaku Zasshi; 1999 Jun; 90(6):279-85. PubMed ID: 10423924
[TBL] [Abstract][Full Text] [Related]
4. Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy.
Timmer-Bonte JN; Adang EM; Termeer E; Severens JL; Tjan-Heijnen VC
J Clin Oncol; 2008 Jan; 26(2):290-6. PubMed ID: 18182670
[TBL] [Abstract][Full Text] [Related]
5. Use of hematopoietic colony-stimulating factors: the American Society of Clinical Oncology survey. The Health Services Research Committee of the American Society of Clinical Oncology.
Bennett CL; Smith TJ; Weeks JC; Bredt AB; Feinglass J; Fetting JH; Hillner BE; Somerfield MR; Winn RJ
J Clin Oncol; 1996 Sep; 14(9):2511-20. PubMed ID: 8823330
[TBL] [Abstract][Full Text] [Related]
6. [Bone marrow suppression--including guidelines for the appropriate use of G-CSF].
Watanabe T
Gan To Kagaku Ryoho; 2003 Jun; 30(6):755-9. PubMed ID: 12852340
[TBL] [Abstract][Full Text] [Related]
7. The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients.
Zielinski CC; Awada A; Cameron DA; Cufer T; Martin M; Aapro M
Eur J Cancer; 2008 Feb; 44(3):353-65. PubMed ID: 18191396
[TBL] [Abstract][Full Text] [Related]
8. Use of antimicrobial agents and granulocyte colony stimulating factors for febrile neutropenia in cancer patients in a tertiary care hospital in India.
Roy V; Saxena D; Agarwal M; Bahadur AK; Mishra B
Indian J Cancer; 2010; 47(4):430-6. PubMed ID: 21131758
[TBL] [Abstract][Full Text] [Related]
9. Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a representative sample survey in Germany.
Link H; Nietsch J; Kerkmann M; Ortner P;
Support Care Cancer; 2016 Jan; 24(1):367-376. PubMed ID: 26081593
[TBL] [Abstract][Full Text] [Related]
10. The use and effectiveness of granulocyte colony-stimulating factor in primary prophylaxis for febrile neutropenia in the outpatient setting.
Tuffaha HW; Treish IM; Zaru L
J Oncol Pharm Pract; 2008 Sep; 14(3):131-8. PubMed ID: 18524866
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization.
Crea F; Giovannetti E; Zinzani PL; Danesi R
Crit Rev Oncol Hematol; 2009 Oct; 72(1):21-44. PubMed ID: 19111474
[TBL] [Abstract][Full Text] [Related]
12. [Evidence-based management of neutropenia and fever].
Ishiguro H; Fung MC; Sakata T; Morizane T; Adachi S
Gan To Kagaku Ryoho; 2003 Sep; 30(9):1365-71. PubMed ID: 14518423
[TBL] [Abstract][Full Text] [Related]
13. Role of granulocyte colony stimulating factor (G-CSF) in chemotherapy induced neutropenia.
Ghalaut PS; Sen R; Dixit G
J Assoc Physicians India; 2008 Dec; 56():942-4. PubMed ID: 19322972
[TBL] [Abstract][Full Text] [Related]
14. Novel strategies for granulocyte colony-stimulating factor treatment of severe prolonged neutropenia suggested by mathematical modeling.
Shochat E; Rom-Kedar V
Clin Cancer Res; 2008 Oct; 14(20):6354-63. PubMed ID: 18927273
[TBL] [Abstract][Full Text] [Related]
15. Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines.
Heuser M; Ganser A; Bokemeyer C; ; ;
Semin Hematol; 2007 Jul; 44(3):148-56. PubMed ID: 17631179
[TBL] [Abstract][Full Text] [Related]
16. Optimal use of recombinant granulocyte colony-stimulating factor with chemotherapy for solid tumors.
Danova M; Barni S; Del Mastro L; Danesi R; Pappagallo GL
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1303-13. PubMed ID: 21916584
[TBL] [Abstract][Full Text] [Related]
17. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy.
Shayne M; Crawford J; Dale DC; Culakova E; Lyman GH;
Breast Cancer Res Treat; 2006 Dec; 100(3):255-62. PubMed ID: 16705366
[TBL] [Abstract][Full Text] [Related]
18. Granulocytic growth factors and cancer-related neutropenia: limited effects.
Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
[TBL] [Abstract][Full Text] [Related]
19. G-CSF guideline adherence in Germany, an update with a retrospective and representative sample survey.
Link H; Kerkmann M; Holtmann L; Ortner P;
Support Care Cancer; 2019 Apr; 27(4):1459-1469. PubMed ID: 30374765
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte-colony-stimulating factor in elderly patients receiving chemotherapy for breast and gynaecological cancers: results of a French survey.
Falandry C; Krakowski I; Curé H; Carola E; Soubeyran P; Guérin O; Freyer G
Anticancer Res; 2014 Sep; 34(9):5007-15. PubMed ID: 25202084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
